biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Here's the bottom line.

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Dec 13, 2022 10:26pm

181 Views

Post# 35170016

RE:RE:RE:RE:RE:RE:Here's the bottom line.

Ugh! That's gobbledeegook, pof.

Go read the resulting ownership details in this table.

Tell us that the loss of controlling interest by the curent shareholders of both companies isn't a worrisome thing.

No, xB3 is not in a position to move forward. It's a technology. It can't move itself forward. The question is, who will do it and who will benefit from it?

Your attempt at informed language is coming across as mostly word salad.

jd

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec